6QC Stock Overview
Researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Towa Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥19.70 |
| 52 Week High | JP¥20.60 |
| 52 Week Low | JP¥15.50 |
| Beta | -0.086 |
| 1 Month Change | 11.30% |
| 3 Month Change | 4.23% |
| 1 Year Change | 24.68% |
| 3 Year Change | -13.18% |
| 5 Year Change | n/a |
| Change since IPO | 19.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6QC | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.5% | 2.2% | 1.7% |
| 1Y | 24.7% | -15.0% | 9.4% |
Return vs Industry: 6QC exceeded the German Pharmaceuticals industry which returned -14.7% over the past year.
Return vs Market: 6QC exceeded the German Market which returned 9.6% over the past year.
Price Volatility
| 6QC volatility | |
|---|---|
| 6QC Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6QC has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 6QC's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1951 | 4,588 | Itsuro Yoshida | www.towayakuhin.co.jp |
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It also offers IT service related to healthcare; and disease risk testing services.
Towa Pharmaceutical Co., Ltd. Fundamentals Summary
| 6QC fundamental statistics | |
|---|---|
| Market cap | €973.32m |
| Earnings (TTM) | €96.56m |
| Revenue (TTM) | €1.49b |
10.1x
P/E Ratio0.7x
P/S RatioIs 6QC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6QC income statement (TTM) | |
|---|---|
| Revenue | JP¥243.94b |
| Cost of Revenue | JP¥155.89b |
| Gross Profit | JP¥88.06b |
| Other Expenses | JP¥72.28b |
| Earnings | JP¥15.78b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 320.45 |
| Gross Margin | 36.10% |
| Net Profit Margin | 6.47% |
| Debt/Equity Ratio | 134.1% |
How did 6QC perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield19%
Payout RatioDoes 6QC pay a reliable dividends?
See 6QC dividend history and benchmarks| Towa Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Mar 28 2025 |
| Dividend Pay Date | Jun 26 2025 |
| Days until Ex dividend | 78 days |
| Days until Dividend pay date | 168 days |
Does 6QC pay a reliable dividends?
See 6QC dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 09:24 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Towa Pharmaceutical Co., Ltd. is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |